TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of Rheumatology
Division of General Internal Medicine
更新時間：2023-09-19
許秉寧HSU, PING-NING
- Principal Investigator
- Clinical Trial Experience (year) 17 years 9 個月
Publication
11Publications
1
Chyuan IT, Chu CL, Hsu PN. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies. Cancers (Basel). 2021 Mar 10;13(6):1188. doi: 10.3390/cancers13061188. PMID: 33801815; PMCID: PMC7998672.
2
Liang TH, Lee CS, Lee SS, Wu CS, Chen KH, Hsu PN, Lin HY. Efficacy and Safety of Opinercept Tumor Necrosis Factor Inhibitor Therapy for Drug-Refractory Rheumatoid Arthritis: A Randomized Clinical Trial. Arch Rheumatol. 2020 Jan 8;35(2):170-179. doi: 10.46497/ArchRheumatol.2020.7464. PMID: 32851365; PMCID: PMC7406163.
3
Chyuan IT, Hsu PN. TRAIL regulates T cell activation and suppresses inflammation in autoimmune diseases. Cell Mol Immunol. 2020 Dec;17(12):1281-1283. doi: 10.1038/s41423-020-0410-2. Epub 2020 Mar 24. PMID: 32210394; PMCID: PMC7784853.
4
Sung CC, Horng JH, Siao SH, Chyuan IT, Tsai HF, Chen PJ, Hsu PN. Asialo GM1-positive liver-resident CD8 T cells that express CD44 and LFA-1 are essential for immune clearance of hepatitis B virus. Cell Mol Immunol. 2021 Jul;18(7):1772-1782. doi: 10.1038/s41423-020-0376-0. Epub 2020 Feb 28. PMID: 32111985; PMCID: PMC8245504.
5
Wu CS, Chyuan IT, Chiu YL, Chen WL, Shen CY, Hsu PN. Preserved specific anti-viral T-cell response but associated with decreased lupus activity in SLE patients with cytomegalovirus infection. Rheumatology (Oxford). 2020 Nov 1;59(11):3340-3349. doi: 10.1093/rheumatology/keaa143. PMID: 32306043.
6
van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24. PMID: 30666826; PMCID: PMC6593705.
7
Chen DY, Hsu PN, Tang CH, Claxton L, Valluri S, Gerber RA. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. J Med Econ. 2019 Aug;22(8):777-787. doi: 10.1080/13696998.2019.1606813. Epub 2019 May 15. PMID: 30982378.
8
Liao HJ, Tsai HF, Wu CS, Chyuan IT, Hsu PN. TRAIL inhibits RANK signaling and suppresses osteoclast activation via inhibiting lipid raft assembly and TRAF6 recruitment. Cell Death Dis. 2019 Jan 28;10(2):77. doi: 10.1038/s41419-019-1353-3. PMID: 30692521; PMCID: PMC6349873.
9
Chyuan IT, Tsai HF, Wu CS, Hsu PN. TRAIL suppresses gut inflammation and inhibits colitogeic T-cell activation in experimental colitis via an apoptosis-independent pathway. Mucosal Immunol. 2019 Jul;12(4):980-989. doi: 10.1038/s41385-019-0168-y. Epub 2019 May 11. PMID: 31076664; PMCID: PMC7746525.
10
Kuo SH, Wu MS, Yeh KH, Lin CW, Hsu PN, Chen LT, Cheng AL. Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers (Basel). 2019 Apr 17;11(4):547. doi: 10.3390/cancers11040547. PMID: 30999581; PMCID: PMC6520890.
1
2
